Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 8/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | TLR3 | O15455 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8821061 | 0.82 | GABRA1 (0.48) | GABRA1GABRG2GABRB3HTR1DHTR1B | |
| SCHEMBL11760240 | 0.77 | CHEK1 (0.46) | GABRA1GABRG2GABRB3KDM4EMEN1 | |
| SCHEMBL24374968 | 0.75 | HTR1D (0.38) | GABRA1GABRG2GABRB3HTR1DHTR1B | |
| SCHEMBL29954096 | 0.73 | MEN1 (0.54) | KDM4EMEN1RECQLKMT2ANR3C1 | |
| SCHEMBL1779012 | 0.73 | MEN1 (0.54) | KDM4EMEN1RECQLKMT2ANR3C1 | |
| SCHEMBL23231411 | 0.68 | KMT2A (0.46) | GABRA1GABRG2GABRB3LIMK1LIMK2 | |
| SCHEMBL7028358 | 0.68 | HTR1D (0.48) | GABRA1GABRG2GABRB3HTR1DHTR1B | |
| SCHEMBL8323656 | 0.67 | ERN1 (0.60) | ELANEPRTN3 | |
| SCHEMBL8409559 | 0.67 | TRIM24 (0.60) | ELANEPRTN3 | |
| SCHEMBL7531725 | 0.66 | ELANE (0.50) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381170-A1 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381170-A1 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2022086851-A1 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-1997046559-A1 | PROCESS FOR PREPARING 9-HYDROXYELLIPTICINE | TANABE SEIYAKU CO., LTD. (JP) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381170-A1 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | RBM39, HNRNPC, HNRNPH3 | GABRA1 3866/4885GABRG2 3815/4885GABRB3 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.